Fight For Lipitor: FDA Calls For Dismissal Of Mylan's Plea On Ranbaxy's AIP
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The U.S. Food and Drug Administration has filed for dismissal of Mylan's March 18 motion that sought a declaratory judgement to enforce provisions of the Application Integrity Policy against Ranbaxy, calling for an immediate denial of the ANDA for Pfizer's leading cholesterol-lowering agent Lipitor (atorvastatin) to the Indian company
You may also be interested in...
Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
Questions during an April 28 court hearing suggest Mylan Pharmaceuticals Inc. may have a difficult time persuading a federal judge that it has standing, at this time, to force an FDA determination on generic marketing exclusivity rights for Pfizer's Lipitor
Lipitor Generics: Judge Questions Mylan's Right To Sue Over Ranbaxy Marketing Exclusivity
Questions during an April 28 court hearing suggest Mylan Pharmaceuticals Inc. may have a difficult time persuading a federal judge that it has standing, at this time, to force an FDA determination on generic marketing exclusivity rights for Pfizer's Lipitor
Mylan Sues FDA Alleging Inaction And Failure To Share Clarity On Ranbaxy's Atorvastatin Filings
MUMBAI - Two months after settling a patent litigation with Pfizer Inc. for cholesterol-reducing agent Lipitor (atorvastatin), generic drugs major Mylan Pharmaceuticals Inc. has charged that U.S. FDA's failure to decide and disclose critical information related to Ranbaxy Laboratories' Ltd. abbreviated new drug application for atorvastatin is "unlawful, arbitrary and capricious.